

15864 US PTO  
 0/82711

041904

17638 U.S.P.T.O.  
 041904

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility application contents

1.  **Specification** [Total Pages 101]  
 (Includes application cover sheet, description, claims, and abstract)
2.  **Drawings** [Total Sheets 14]
3.  **Oath or Declaration** [Total Pages \_\_\_\_\_]
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20B completed)
4.  **Application Data Sheet.** See 37 CFR 1.76  
 [Total Pages \_\_\_\_\_]
5.  **Nucleotide and/or Amino Acid Sequence Submission** (if applicable, all necessary)
  - a.  Computer Readable Form (CRF)  
**-OR-**
  - Statement under 37 CFR 1.821(e) (see Box 21 for statement)
  - Specification Sequence Listing on:
    - i.  CD-ROM or CD-R (2 copies); or
    - ii.  paper [Total Pages \_\_\_\_\_]
  - c.  The contents of the computer readable form of the sequence listing and the sequence listing in the specification of the application are the same.

Attorney Docket No.: 13099.0023U2

First Inventor: TACHDJIAN *et al.*

Title: "SUBSTITUTED DIHYDRONAPHTHALENE AND ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES"

Express Mail Label No.: EL992076016US

Mail Stop PATENT APPLICATION  
 ADDRESS TO: Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450



6.  **CD-ROM or CD-R** in duplicate, large tables or Computer Program (Appendix)

**ACCOMPANYING APPLICATION PARTS:**

7.  Copy of Assignment
8.  37 CFR 3.73(b) Statement (when there is an assignee)
9.  Power of Attorney
10.  English Translation Document (if applicable)
11.  Information Disclosure Statement/PTO-1449
  - Copies of IDS Citations [Total Citations \_\_\_\_\_]
12.  Preliminary Amendment
13.  Certified Copy of Priority Document(s) (if foreign priority is claimed)
14.  Nonpublication Request under 35 USC 122(b)(2)(B)(i) (Must attach form PTO/SB/35 or equivalent).
15.  Authorization to Treat Reply Requiring Extension of Time as Incorporating Petition for Extension of Time (2 pages)
16.  Return Receipt Postcard (MPEP 503)
17.  Other: \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

18. The **FILING FEE** is calculated as follows: (Claims as filed, less any claims cancelled by Amendment)

Claims	Number Filed	Number Extra	Rate	Basic Fee \$770.00
Total claims	53 - 20 =	33	X \$18.00	\$594.00
Independent claims	2 - 3 =	0	X \$86.00	\$0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				\$0.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$1,364.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees are reduced by ½.				\$0.00
<b>TOTAL FILING FEE =</b>				\$1,364.00

20A.	<input checked="" type="checkbox"/>	This application is an original application ( <u>not</u> a continuation, divisional or continuation-in-part) claiming priority under 35 U.S.C. § 111(b) of U.S. Provisional Application Serial No. 60/464,388, filed April 18, 2003.
20B.	<input type="checkbox"/>	This application is a <input type="checkbox"/> continuation-in-part / <input type="checkbox"/> continuation / <input type="checkbox"/> divisional of prior Application No. _____. The prior application was assigned to Examiner _____, Group Art Unit _____. <b>The entire disclosure of the prior application is considered a part of the disclosure of the accompanying application and is hereby incorporated by reference.</b>
	<input type="checkbox"/>	This application is a continuation or divisional application ( <u>not</u> a continuation-in-part) that: (i) names as inventors the same or fewer than all the inventors named in the prior application; and (ii) contains no matter that would have been new matter in the prior application; and (iii) a copy of the executed oath or declaration in the prior application, showing the signature or an indication thereon that it was signed: <input type="checkbox"/> is enclosed. <input type="checkbox"/> will follow.
	<input type="checkbox"/>	This application is a continuation or divisional application ( <u>not</u> a continuation-in-part) that is being filed by less than all the inventors named in the prior application. In accordance with 37 C.F.R. §1.63(d)(2), the Commissioner is requested to delete the name(s) of the following person who are not inventors of the invention being claimed in this application:
	<input type="checkbox"/>	This application is a continuation-in-part, continuation or divisional application naming an inventor not named in the prior application. A newly executed oath or declaration: <input type="checkbox"/> is enclosed. <input type="checkbox"/> will follow.
21.	<input type="checkbox"/>	A sequence listing in computer readable form in compliance with 37 C.F.R. §§ 1.821-1.825 was submitted on _____ in prior Application No. _____, filed _____. Pursuant to 37 C.F.R. § 1.821(e), applicant hereby requests that the computer readable form of the sequence listing submitted in the above-referenced prior application be used as the computer readable form of the sequence listing for the new application. The paper or compact disk copy of the Sequence Listing in the new application is identical to the computer readable copy filed in the prior application.
22.	<input type="checkbox"/>	This application claims foreign priority benefits under 35 USC 119(a)-(d) or 365(b) of any foreign application(s) listed below, or under 35 USC 365(a) or 365(b) of any PCT application listed below. Application No. _____ Country: _____ Day/Month/Year Filed: _____
23. Address all correspondence to the address associated with: Mark A. Murphy, Ph.D. CUSTOMER NO. 23859		
Name of Attorney/Agent:	Mark A. Murphy, Ph.D.	Registration No.: 42,915
Signature:		Date: April 19, 2004
<b>Certificate of Express Mailing Under 37 C.F.R. § 1.10</b>		
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992076016US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.		
 Mark A. Murphy, Ph.D.		 Date

041904  
17638 U.S.PTO

ATTORNEY DOCKET NO. 13099.0023U2  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of )  
TACHDJIAN *et al.* ) Confirmation No.: Unassigned  
Application No.: Unassigned ) Group Art Unit: Unassigned  
Filing Date: Concurrently ) Examiner: Unassigned  
FOR: "SUBSTITUTED DIHYDRONAPHTHALENE )  
AND ISOCHROMAN COMPOUNDS FOR THE )  
TREATMENT OF METABOLIC DISORDERS, )  
CANCER AND OTHER DISEASES" )

**AUTHORIZATION TO TREAT REPLY REQUIRING EXTENSION OF TIME**  
**AS INCORPORATING PETITION FOR EXTENSION OF TIME**

MAIL STOP PATENT APPLICATION  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859

April 19, 2004

Sir:

Pursuant to 37 C.F.R. §1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time

**ATTORNEY DOCKET NO. 13099.0023U2  
PATENT**

for the appropriate length of time.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.


  
\_\_\_\_\_  
Mark A. Murphy, Ph.D.  
Registration No. 42,915

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859  
(678) 420-9300 Phone  
(678) 420-9301 Fax

**CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10**

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992076016US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

  
\_\_\_\_\_  
Mark A. Murphy, Ph.D.

  
\_\_\_\_\_  
Date